The state of cancer care in Russia: malignant tumors of the skin (C44). One- and five-years survival of patients, age characteristics. Part II

Abstract

Pancreas cancer (С25) is a cancer with an unfavorable prognosis, remains one of the most lethal types of cancer, at the national level mortality exceeds morbidity. The analysis of patient survival at the population level on the scale of federal districts is not carried out in Russia with the exception of the North-West Federal District. Considering that the levels of standardized rates of morbidity and mortality from pancreas cancer are close in Russia and NWFD, and the value of index of accuracy practically coincide, the results of the population cancer registry (PCR) of the NWFD RF actually characterize the state of cancer care on average in Russia, with the exception of autonomous districts. The aim of the second stage of the study was to identify the true state of the effectiveness of the oncological service in Russia by calculating a key parameter – evaluating its performance, specifically, calculating the leading parameter – the survival rate of patients, taking into account the stage, localization, histological structure, and the possibility of curing patients The conducted research made it possible to determine the effectiveness of providing specialized oncological care to patients with pancreas cancer at the federal district level. An increase in the one–year observed survival rate for the period from 2000 to 2004 to 2015-2019 was established from 16.0 to 21.8% or by 36.3%, and five–year from 5.1 to 6.0%. The median survival rate did not reach 4 years. A significant difference in the levels of one-year survival of patients in different age groups has been established. Significant defects in the distribution of patients according to the stage of the disease were revealed. The specification of patient survival by detailed localization groups and major histotypes of tumors was studied.

Keywords

malignant tumors / skin cancer (С44) / North-West federal district of Russian Federation / survival of patients, 1-year, 5-year / localization and histological study / database / Population Cancer Registry

References

[1] Berrino F., Sant M., Verdecchia V., Capocaccia R., Hakulinen T., Estéve J., eds. Survival of cancer patients in Europe: the EUROCARE Study (IARC Scientific Publications No. 132). Lyon: International Agency for Research on Cancer, 1995.

[2] Berrino F., Capocaccia R., Coleman M. P., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. Survival of cancer patients in Europe: the EUROCARE-2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.

[3] Berrino F., Capocaccia R., Coleman M.P., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. Survival of cancer patients in Europe: the EUROCARE-2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.

[4] Berrino F., Capocaccia R., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. EUROCARE-3: the survival of cancer patients diagnosed in Europe during 1990–94. Ann Oncol 2003; 14 (Suppl. 5):pp1–155

[5] Capocaccia R., Gavin A., Hakulinen T., Lutz J. M., Sant M. (eds.) Survival of cancer patients in Europe, 1995–2002. The EUROCARE-4 study. Eur J Cancer 2009; 45.

[6] de Angelis R., Sant M., Coleman M., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., Bielska-Lasota M., Engholm G., Nennecke A., Siesling S., Berrino F., Capocaccia R., and the EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol 2014; 15:23–34. doi: 10.1016/S1470–2045(13)70546-1

[7] De Angelis R., Sant M., Coleman M., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., Bielska-Lasota M., Engholm G., Nennecke A., Siesling S., Berrino F., Capocaccia R., and the EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol 2014;15:23–34. doi: 10.1016/ S1470-2045(13)70546-1

[8] GLOBOCAN2018: estimated cancer incidence, mortality and prevalence worldwide in 2012 [accessed 03.11.2018]. Available at: http://gco.iarc.fr/today/online-analysis-pie

[9] GLOBOCAN2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [accessed 15.04.2017]. Available at: http://globocan.iarc.fr/Default.aspx

[10] Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–263.

[11] Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–263.

[12] Siegel R. L., Giaquinto A. N., Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12–49.

[13] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12–49.

[14] Welch H. G., Mazer B. L., Adamson A. S. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med 2021;384: 72–79.

[15] Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med 2021; 384: 72–79.

[16] Merabishvili V. M. Survival of cancer patients. St.Petersburg: KOSTA, 2011. – 330 p. (In Russ.)

[17] Мерабишвили В. М. Выживаемость онкологический больных. Выпуск второй. Часть I. – СПб.: КОСТА, 2011. – 330 с.

[18] Merabishvili V. M. Survival of cancer patients. St.Petersburg: KOSTA, 2011. – 408 p. (In Russ.)

[19] Мерабишвили В. М. Выживаемость онкологический больных. Выпуск второй. Часть II. – СПб.: КОСТА, 2011. – 408 с.

[20] Berezkin DP. The study of survival and individual prognosis in malignant tumors. General oncology. Napalkov NP, ed. L. 1989:608–632 (In Russ.).

[21] Березкин Д. П. Изучение выживаемости и индивидуальный прогноз при злокачественных опухолях. Общая онкология. Под ред. Н. П. Напалкова. Л..1989: 608–632.

[22] Merabishvili V. M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part II. – St. Petersburg: LLC “Publishing and printing company „COSTA“», 2011. – 248s. (In Russ.)

[23] Мерабишвили В. М. Онкологическая статистика (традиционные методы, новые информационные технологии): руководство для врачей. Часть II. – СПб.: ООО «Издательско-полиграфическая компания «КОСТА», 2011. – 248 с.

[24] Berezkin D. P. Methods of studying the survival of cancer patients. Methodological recommendations. L.1982:24 (In Russ.).

[25] Березкин Д. П. Методы изучения выживаемости онкологических больных. Методические рекомендации. Л. 1982:24.

[26] Ivanov O. A., Syharev A. E., Starinskii V. V., Egorov S. N. The method of processing the database of cancer patients (survival rate). Methodological recommendations (97/85). M.1997:23 (In Russ.).

[27] Иванов О. А., Сухарев А. Е., Старинский В. В., Егоров С. Н. Метод обработки базы данных онкологических больных (выживаемости). Методические рекомендации No. 97/85. М. 1997:23.

[28] Merabishvili V. M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part I. St. Petersburg: LLC “Publishing and printing company „COSTA“», 2011. 221 p. (In Russ.).

[29] Мерабишвили В. М. Онкологическая статистика (традиционные методы, новые информационные технологии): руководство для врачей. Часть I. – СПб.: ООО «Издательско-полиграфическая компания «КОСТА», 2011. – 221 с.

[30] Merabishvili V. M. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express-information. Fifth Issue. Editors: Prof. A. M. Belyaev, Prof. A. M. Shcherbakov. – St.Petersburg: T8 Publishing technologies, 2020. – 236 p. (In Russ.).

[31] Мерабишвили В. М. Злокачественные новообразования в Северо-Западном федеральном округе России (заболеваемость, смертность, достоверность учета, выживаемость больных). Экспресс-информация. Выпуск пятый. / Под ред. проф. А. М. Беляева, проф. А. М. Щербакова. – СПб.: Т. 8 Издательские технологии, 2020. – 236 с.

[32] Merabishvili V. M. Malignant tumors in the North-West Federal Region of Russia (Morbidity, mortality, prevalence rate, survival). Express-information. Sixth Issue. Manual for doctors / ed. by prof A. M. Belyaev– SPb: T8 Publishing technologies, 2023. – 485 p. (In Russ.).

[33] Мерабишвили В. М. Злокачественные новообразования в Северо-Западном федеральном округе России (заболеваемость, смертность, достоверность учета, выживаемость больных). Экспресс-информация. Выпуск шестой. Пособие для врачей / Под ред. чл.-корр. РАН, проф. А. М. Беляева. – СПб, 2023.

[34] Rogers H. W., Weinstock M. A., Harris A. R., Hinckley M. R., Feldman S. R., Fleischer A. B., Coldiron B. M. Incidence estimate of nonmelanoma skin cancer in the United States, 2006 // Arch Dermatol. – 2010. – Vol. 146, No. 3. – P. 283–7.

[35] Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer // Br J Dermatol. – 2012. – Vol. 166, No. 5. – P. 1069–80.

[36] Jayaraman S. S., Rayhan D. J., Hazany S., Kolodney M. S. Mutational landscape of basal cell carcinomas by whole-exome sequencing // J Invest Dermatol. – 2014. – Vol. 134, No. 1. – P. 213–220.

[37] Kuo K. Y., Batra P., Cho H. G., Li S., Chahal H. S., Rieger K. E., Tang J. Y., Sarin K. Y. Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution // J Am Acad Dermatol. – 2017. – Vol. 77, No. 2. – P. 233–234 e2.

[38] Reifenberger J., Wolter M., Knobbe C. B., Kohler B., Schonicke A., Scharwachter C., Kumar K., Blaschke B., Ruzicka T., Reifenberger G. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas // Br J Dermatol. – 2005. – Vol. 152, No. 1. – P. 43–51.

[39] Kadouch D. J., Leeflang M. M., Elshot Y. S., Longo C., Ulrich M., van der Wal A. C., Wolkerstorfer A., Bekkenk M. W., de Rie M. A. Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma // J Eur Acad Dermatol Venereol. – 2017. – Vol. 31, No. 10. – P. 1641–1648.

[40] Lallas A., Argenziano G., Zendri E., Moscarella E., Longo C., Grenzi L., Pellacani G., Zalaudek I. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring // Expert Rev Anticancer Ther. – 2013. – Vol. 13, No. 5. – P. 541–58.

[41] Rowe D. E., Carroll R. J., Day C. L., Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up // J Dermatol Surg Oncol. – 1989. – Vol. 15, No. 3. – P. 315–28.

[42] Avril M. F., Auperin A., Margulis A., Gerbaulet A., Duvillard P., Benhamou E., Guillaume J. C., Chalon R., Petit J. Y., Sancho-Garnier H., Prade M., Bouzy J., Chassagne D. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study // Br J Cancer. – 1997. – Vol. 76, No. 1. – P. 100–6.

[43] Petit J. Y., Avril M. F., Margulis A., Chassagne D., Gerbaulet A., Duvillard P., Auperin A., Rietjens M. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face // Plast Reconstr Surg. – 2000. – Vol. 105, No. 7. – P. 2544–51.

[44] Kuijpers D. I., Thissen M. R., Berretty P. J., Ideler F. H., Nelemans P. J., Neumann M. H. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma // Dermatol Surg. – 2007. – Vol. 33, No. 5. – P. 579–87.

[45] Bath-Hextall F., Ozolins M., Armstrong S. J., Colver G. B., Perkins W., Miller P. S., Williams H. C., Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma study g. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial // Lancet Oncol. – 2014. – Vol. 15, No. 1. – P. 96–105.

[46] Blixt E., Nelsen D., Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone // Dermatol Surg. – 2013. – Vol. 39, No. 5. – P. 719–25.

[47] Mohs F. E. Chemosurgical treatment of cancer of the face; a microscopically controlled method of excision // Arch Derm Syphilol. – 1947. – Vol. 56, No. 2. – P. 143–56.

[48] Mohs F. E. Chemosurgery: a method for the microscopically controlled excision of cancer of the skin and lips // Geriatrics. – 1959. – Vol. 14, No. 2. – P. 78–88.

[49] Alcalay J. The value of mohs surgery for the treatment of nonmelanoma skin cancers // J Cutan Aesthet Surg. – 2012. – Vol. 5, No. 1. – P. 1–2.

[50] Alcalay J. Mohs Mapping in the Cloud: An Innovative Method for Mapping Tissue in Mohs Surgery // J Drugs Dermatol. – 2015. – Vol. 14, No. 10. – P. 1127–30.

[51] Siddiqui F. S., Leavitt A. Mohs Micrographic Surgery Appropriate Use Criteria (AUC) Guidelines // StatPearls. – Treasure Island (FL) ineligible companies. Disclosure: Adam Leavitt declares no relevant financial relationships with ineligible companies., 2024.

[52] Kofler L., Kofler K., Schulz C., Breuninger H., Hafner H. M. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma // Arch Dermatol Res. – 2021. – Vol. 313, No. 2. – P. 119–126.

[53] Durham A. B., Lowe L., Malloy K. M., McHugh J. B., Bradford C. R., Chubb H., Johnson T. M., McLean S. A. Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma on the Head and Neck // JAMA Otolaryngol Head Neck Surg. – 2016. – Vol. 142, No. 12. – P. 1171–1176.

[54] Sims J. R., Grotz T. E., Pockaj B. A., Joseph R. W., Foote R. L., Otley C. C., Weaver A. L., Jakub J. W., Price D. L. Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients // Surg Oncol. – 2018. – Vol. 27, No. 1. – P. 11–17.

[55] Allen N. C., Martin A. J., Snaidr V. A., Eggins R., Chong A. H., Fernandez-Penas P., Gin D., Sidhu S., Paddon V. L., Banney L. A., Lim A., Upjohn E., Schaider H., Ganhewa A. D., Nguyen J., McKenzie C. A., Prakash S., McLean C., Lochhead A., Ibbetson J., Dettrick A., Landgren A., Allnutt K. J., Allison C., Davenport R. B., Mumford B. P., Wong B., Stagg B., Tedman A., Gribbin H., Edwards H. A., De Rosa N., Stewart T., Doolan B. J., Kok Y., Simpson K., Low Z. M., Kovitwanichkanont T., Scolyer R. A., Dhillon H. M., Vardy J. L., Chadban S. J., Bowen D. G., Chen A. C., Damian D. L. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients // N Engl J Med. – 2023. – Vol. 388, No. 9. – P. 804–812.

[56] Chen A. C., Martin A. J., Choy B., Fernandez-Penas P., Dalziell R. A., McKenzie C. A., Scolyer R. A., Dhillon H. M., Vardy J. L., Kricker A., St George G., Chinniah N., Halliday G. M., Damian D. L. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention // N Engl J Med. – 2015. – Vol. 373, No. 17. – P. 1618–26.

[57] Chen A. C., Martin A. J., Choy B., Fernandez-Penas P., Dalziell R. A., McKenzie C. A., Scolyer R. A., Dhillon H. M., Vardy J. L., Kricker A., St George G., Chinniah N., Halliday G. M., Damian D. L.A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention // N Engl J Med. – 2015. – Vol. 373, No. 17. – P. 1618–26.

[58] Newman J. G., Hall M. A., Kurley S. J., Cook R. W., Farberg A. S., Geiger J. L., Koyfman S. A. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review // Head Neck. – 2021. – Vol. 43, No. 9. – P. 2822–2843.

[59] Bhatia S., Brohl A. S., Brownell I., Chandra S., Dakhil S., Ernstoff M. S., Fecher L. A., Gooley T., Hanna G. J., Hibbert R., Kelly C. M., Kiriluk S. M., Nghiem P., Nguyen V., Pelz N., Poisson A. A., Price K. A.R., Sondak V. K., Thompson J. A., Tykodi S. S. ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 // Journal of Clinical Oncology. – 2018. – Vol. 36, No. 15_suppl. – P. TPS9605-TPS9605.

[60] Bhatia S., Brohl A. S., Brownell I., Chandra S., Dakhil S., Ernstoff M. S., Fecher L. A., Gooley T., Hanna G. J., Hibbert R., Kelly C. M., Kiriluk S. M., Nghiem P., Nguyen V., Pelz N., Poisson A. A., Price K. A.R., Sondak V. K., Thompson J. A., Tykodi S. S. ADAM trial: A multicenter, rando mized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 // Journal of Clinical Oncology. – 2018. – Vol. 36, No. 15_suppl. – P. TPS9605–TPS9605.

[61] Gross N. D., Miller D. M., Khushalani N. I., Divi V., Ruiz E. S., Lipson E. J., Meier F., Su Y. B., Swiecicki P. L., Atlas J., Geiger J. L., Hauschild A., Choe J. H., Hughes B. G.M., Schadendorf D., Patel V. A., Homsi J., Taube J. M., Lim A. M., Ferrarotto R., Kaufman H. L., Seebach F., Lowy I., Yoo S. Y., Mathias M., Fenech K., Han H., Fury M. G., Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma // N Engl J Med. – 2022. – Vol. 387, No. 17. – P. 1557–1568.

[62] Alcalay J., Tauber G., Fenig E., Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma // J Drugs Dermatol. – 2015. – Vol. 14, No. 3. – P. 219–23.

[63] Grob J. J., Gonzalez R., Basset-Seguin N., Schachter J., Vornicova O., Bauman J. R., Grange F., Meyer N., Piulats J. M., Zhang E., Gumuscu B., Swaby R. F., Hughes B. G. M. KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC) // Journal of Clinical Oncology. – 2019. – Vol. 37, No. 15_suppl. – P. TPS9598-TPS9598.

[64] Grob J. J., Gonzalez R., Basset-Seguin N., Schachter J., Vornicova O., Bauman J. R., Grange F., Meyer N., Piulats J. M., Zhang E., Gumuscu B., Swaby R. F., Hughes B. G. M. KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC) // Journal of Clinical Oncology. – 2019. – Vol. 37, No. 15_suppl. – P. TPS9598–TPS9598.

[65] Munhoz R. R., Nader-Marta G., de Camargo V. P., Queiroz M. M., Cury-Martins J., Ricci H., de Mattos M. R., de Menezes T. A.F., Machado G. U.C., Bertolli E., Barros M., de Souza C. E., Franke F., Ferreira F. O., Feher O., de Castro G., Jr. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma // Cancer. – 2022. – Vol. 128, No. 24. – P. 4223–4231.

[66] Munhoz R. R., Nader-Marta G., de Camargo V. P., Queiroz M. M., Cury-Martins J., Ricci H., de Mattos M. R., de Menezes T. A.F., Machado G. U. C., Bertolli E., Barros M., de Souza C. E., Franke F., Ferreira F. O., Feher O., de Castro G., Jr. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma // Cancer. – 2022. – Vol. 128, No. 24. – P. 4223–4231.

[67] Migden M. R., Rischin D., Schmults C. D., Guminski A., Hauschild A., Lewis K. D., Chung C. H., Hernandez-Aya L., Lim A. M., Chang A. L.S., Rabinowits G., Thai A. A., Dunn L. A., Hughes B. G.M., Khushalani N. I., Modi B., Schadendorf D., Gao B., Seebach F., Li S., Li J., Mathias M., Booth J., Mohan K., Stankevich E., Babiker H. M., Brana I., Gil-Martin M., Homsi J., Johnson M. L., Moreno V., Niu J., Owonikoko T. K., Papadopoulos K. P., Yancopoulos G. D., Lowy I., Fury M. G. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma // N Engl J Med. – 2018. – Vol. 379, No. 4. – P. 341–351.

[68] Migden M. R., Khushalani N. I., Chang A. L.S., Lewis K. D., Schmults C. D., Hernandez-Aya L., Meier F., Schadendorf D., Guminski A., Hauschild A., Wong D. J., Daniels G. A., Berking C., Jankovic V., Stankevich E., Booth J., Li S., Weinreich D. M., Yancopoulos G. D., Lowy I., Fury M. G., Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial // Lancet Oncol. – 2020. – Vol. 21, No. 2. – P. 294–305.

[69] Marin-Acevedo J. A., Withycombe B. M., Kim Y., Brohl A. S., Eroglu Z., Markowitz J., Tarhini A. A., Tsai K. Y., Khushalani N. I. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma // Cancers (Basel). – 2023. – Vol. 15, No. 12.

[70] Cavalieri S., Bergamini C., Alfieri S., Resteghini C., Nuzzolese I., Colombo E., Ottini A., Licitra L. Management of patients with skin adnexal carcinomas // EJC Skin Cancer. – 2023. – Vol. 1. – P. 100006.

[71] Kleibert M., Plachta I., Czarnecka A. M., Spalek M. J., Szumera-Cieckiewicz A., Rutkowski P. Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective // Cancers (Basel). – 2022. – Vol. 14, No. 4.

[72] de Iuliis F., Amoroso l., Taglieri l., Vendittozzi S., Blasi l., Salerno G., Lanza R., Scarpa S. Chemotherapy of Rare Skin Adnexal Tumors: A Review of Literature // Anticancer Research. – 2014. – Vol. 34, No. 10. – P. 5263–5268.

[73] de Iuliis F., Amoroso L., Taglieri L., Vendittozzi S., Blasi L., Salerno G., Lanza R., Scarpa S. Chemotherapy of Rare Skin Adnexal Tumors: A Review of Literature // Anticancer Research. – 2014. – Vol. 34, No. 10. – P. 5263–5268.

RIGHTS & PERMISSIONS

Eco-Vector